Singapore National Eye Center
Singapore, 168751
NCT Number: NCT00796926
Systane Ultra is at least as efficacious and safe as Refresh Tears in Asian people with Dry Eyes
Looking for future studies?
Notify Me40 year–65 year
All sexes
Interventional
Phase 3
Singapore, 168751
Comparison of efficacy of Systane Ultra and Refresh Tears
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
based on the Salisbury Eye study by Oliver Schein et al. (Does your eye feel dry, gritty, red, watery, crusted, stuck in the morning?) Please see appendix 1.
Exclusion criteria
Four times a day
Other names: Systane Ultra, Alcon
Four times a day
Other names: Refresh, Allergan
Time frame: 6 weeks
Global score calculated from square root( square of (discomfort severityX Sqr(symptom frequency)) Scale from 0 to 100 higher value indicates more adverse symptoms each subscale severity or frequency also has same minimum and maximum
Time frame: 6 weeks
This is graded in the 5 zones of each cornea according to number of spots of corneal fluorescein staining, confluency of spots and presence of filaments if any
Time frame: 6 weeks
Time frame: 6 weeks
Time frame: 6 weeks
Time frame: 6 weeks
This is measured by the TearLab (Ocusense) system
Time frame: 6 weeks
This is determined by anterior segment OCT visante system
Louis Tong
Other Gov
Randomised Controlled Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05656196
Arthritis, Arthritis, Rheumatoid
Taipei, Taiwan
View Trial DetailsNCT03753893
Amaurosis Fugax, Arterial Occlusive Diseases
View Trial DetailsNCT01089985
Conjunctival Diseases, Dry Eye Syndromes
Singapore
View Trial DetailsNCT06771427
Arthritis, Arthritis, Rheumatoid
Taipei, Taiwan
View Trial Details